antiviral and associated therapy - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.28 [0.07, 1.04]< 137%5 studies (5/-)97.1 %some concernnot evaluable moderatecrucial-
deaths 0.80 [0.55, 1.16]< 10%14 studies (14/-)88.3 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.80 [0.43, 1.50]< 10%1 study (1/-)75.7 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.44 [0.20, 0.99]< 179%6 studies (6/-)97.6 %some concernnot evaluable moderatecrucial-
A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 10%1 study (1/-)34.7 %some concernnot evaluable moderateimportant-
clinical deterioration 0.73 [0.41, 1.28]< 120%4 studies (4/-)86.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.08 [1.00, 1.16]> 10%4 studies (4/-)98.1 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.12 [0.85, 1.47]> 113%2 studies (2/-)78.5 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.07 [0.97, 1.18]> 10%1 study (1/-)91.0 %lownot evaluable highimportant-
clinical improvement (time to event analysis only) 1.07 [1.00, 1.16]> 10%3 studies (3/-)97.0 %some concernnot evaluable moderateimportant-
hospitalization 0.74 [0.63, 0.86]< 10%14 studies (14/-)100.0 %some concernlow moderateimportant-
mechanical ventilation 1.08 [0.50, 2.31]< 10%3 studies (3/-)42.6 %some concernnot evaluable moderateimportant-
Recovery (time to event analysis only) 0.79 [0.42, 1.48]> 10%1 study (1/-)23.0 %some concernnot evaluable moderateimportant-
viral clearance 0.90 [0.76, 1.07]> 139%6 studies (6/-)11.9 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.79 [0.59, 1.07]> 148%3 studies (3/-)6.3 %some concernnot evaluable moderateimportant-
viral clearance by day 7 0.91 [0.69, 1.20]> 140%6 studies (6/-)25.5 %some concernnot evaluable moderateimportant-
emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 10%1 study (1/-)99.8 %some concernnot evaluable moderatenon important-
ICU admission 0.82 [0.45, 1.50]< 10%2 studies (2/-)73.5 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 0.79 [0.37, 1.69]< 160%4 studies (4/-)72.9 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.76 [1.10, 2.82]< 10%1 study (1/-)1.0 %lownot evaluable highimportant-
related SAE (TRSAE) 1.01 [0.25, 4.05]< 10%1 study (1/-)49.6 %lownot evaluable highimportant-
serious adverse events 0.53 [0.29, 0.98]< 127%5 studies (5/-)97.9 %some concernnot evaluable moderateimportant-
adverse events 1.10 [0.74, 1.64]< 175%7 studies (7/-)31.6 %some concernnot evaluable moderatenon important-
hyperbilirubinemia 0.66 [0.33, 1.30]< 10%1 study (1/-)88.4 %lownot evaluable highnon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.